Sangoma SANG Q1 2026 Earnings Miss by Significant Key Takeaways Affiliated MGRE Steady at 2402 Awaiting Next Catalyst 20260513 Argan AGX Q1 2026 Earnings Surprise EPS 347 Up Significant Pulse Biosciences CEO Paul A LaViolette Acquires 15000 Shares in OpenMarket Purchase Arm Holdings and Red Hat Collaborate to Advance Agentic AI Stack for Enterprise Workloads Trump Dismisses Concerns Over Powells Continued Tenure at Federal Reserve Goldman Sachs US Sanctions Have Not Significantly Disrupted Russias Crude Exports JK Tyre Unveils Rs 4900 Crore Capex Plan to Boost Capacity by 24 by FY30 NVIDIA and Fortinet Join Forces to Protect AI Workloads in Real Time Analysts Reassess Walmarts Position Amid Evolving Retail Landscape GLUE Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Pipeline Indaptus Therapeutics Q4 2025 Earnings EPS Misses Estimates on Minimal Revenue Stock Surges EGBN Q1 2026 Earnings EPS Surges Past Estimates on Strong Margin and Lower Provisions ST Bancorp Inc Q1 2026 Earnings Earnings Beat Driven by Strong Net Interest Margin MRDN Q1 2026 Earnings Massive EPS Beat Surprises Market SEGG Q1 2025 Earnings Loss Per Share Reported at 014 Stock Declines 545 Franklin Universal Trust FT Edges Higher Amid Modest Trading Activity Blue Foundry Bancorp Holds Steady at 1324 as Support and Resistance Levels Come into Focus Brazil Potash Corp GRO Holds Steady at 250 as Traders Eye Key Levels Core Scientific Warrants CORZW Surge 470 as Bitcoin Mining Sentiment Improves TNL Mediagene TNMG Holds Near Support Amid Modest Decline 60 Degrees Pharmaceuticals SXTP Holds Near Support After Minor Decline Pyrophyte Acquisition Corp II PAII Holds Steady Near 1018 Amid Low Volatility Educational Development Corporation EDUC Holds Steady at 141 Amid Tight Trading Range SouthState Bank SSB Edges Higher Tests Resistance as Support Holds Mayfair Gold Corp MINE Gains 42 as Bullish Momentum Builds Above Key Support SK Hynix Posts Record Profit on AI Chip Demand as Nvidia Supplier SLDB Q1 2026 Earnings WiderThanExpected Loss as PreRevenue Biotech Advances Pipeline Enanta Pharmaceuticals ENTA Dips 3 as Support at 1285 Comes into Focus